|
1
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Biswas S and Rao CM: Epigenetics in
cancer: Fundamentals and beyond. Pharmacol Ther. 173:118–134. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kelley RK and Greten TF: Hepatocellular
carcinoma-origins and outcomes. N Engl J Med. 385:280–282. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giannelli G, Koudelkova P, Dituri F and
Mikulits W: Role of epithelial to mesenchymal transition in
hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ito S, Kinoshita S, Shiraishi N, Nakagawa
S, Sekine S, Fujimori T and Nabeshima YI: Molecular cloning and
expression analyses of mouse betaklotho, which encodes a novel
Klotho family protein. Mech Dev. 98:115–119. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee S, Choi J, Mohanty J, Sousa LP, Tome
F, Pardon E, Steyaert J, Lemmon MA, Lax I and Schlessinger J:
Structures of β-klotho reveal a ‘zip code’-like mechanism for
endocrine FGF signalling. Nature. 553:501–505. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi SY, Lu YW, Richardson J, Min X,
Weiszmann J, Richards WG, Wang Z, Zhang Z, Zhang J and Li Y: A
systematic dissection of sequence elements determining β-Klotho and
FGF interaction and signaling. Sci Rep. 8:110452018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Triantis V, Saeland E, Bijl N,
Oude-Elferink RP and Jansen PL: Glycosylation of fibroblast growth
factor receptor 4 is a key regulator of fibroblast growth factor
19-mediated down-regulation of cytochrome P450 7A1. Hepatology.
52:656–666. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang Z, Xu A and Cheung BMY: The
potential role of fibroblast growth factor 21 in lipid metabolism
and hypertension. Curr Hypertens Rep. 19:282017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen J, Du F, Dang Y, Li X, Qian M, Feng
W, Qiao C, Fan D, Nie Y, Wu K and Xia L: Fibroblast growth factor
19-mediated up-regulation of SYR-related high-mobility group box 18
promotes hepatocellular carcinoma metastasis by transactivating
fibroblast growth factor receptor 4 and Fms-related tyrosine kinase
4. Hepatology. 71:1712–1731. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Poh W, Wong W, Ong H, Aung MO, Lim SG,
Chua BT and Ho HK: Klotho-beta overexpression as a novel target for
suppressing proliferation and fibroblast growth factor receptor-4
signaling in hepatocellular carcinoma. Mol Cancer. 11:142012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Anestopoulos I, Voulgaridou GP,
Georgakilas AG, Franco R, Pappa A and Panayiotidis MI: Epigenetic
therapy as a novel approach in hepatocellular carcinoma. Pharmacol
Ther. 145:103–119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khalili-Tanha G and Moghbeli M: Long
non-coding RNAs as the critical regulators of doxorubicin
resistance in tumor cells. Cell Mol Biol Lett. 26:392021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han TS, Ban HS, Hur K and Cho HS: The
epigenetic regulation of HCC metastasis. Int J Mol Sci.
19:39782018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shen Y, Wei W and Zhou DX: Histone
acetylation enzymes coordinate metabolism and gene expression.
Trends Plant Sci. 20:614–621. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Falkenberg KJ and Johnstone RW: Histone
deacetylases and their inhibitors in cancer, neurological diseases
and immune disorders. Nat Rev Drug Discov. 13:673–691. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsilimigras DI, Ntanasis-Stathopoulos I,
Moris D, Spartalis E and Pawlik TM: Histone deacetylase inhibitors
in hepatocellular carcinoma: A therapeutic perspective. Surg Oncol.
27:611–618. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
You H, Li Q, Kong D, Liu X, Kong F, Zheng
K and Tang R: The interaction of canonical Wnt/β-catenin signaling
with protein lysine acetylation. Cell Mol Biol Lett. 27:72022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu ZY, Tang N, Wang MF, Zhou JC, Wang JL,
Ren HZ and Shi XL: Comprehensive pan-cancer genomic analysis
reveals PHF19 as a carcinogenic indicator related to immune
infiltration and prognosis of hepatocellular carcinoma. Front
Immunol. 12:7810872022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shang L, Ren H, Wang S, Liu H, Hu A, Gou
P, Lin Y, Zhou J, Zhu W and Shi X: SS-31 protects liver from
ischemia-reperfusion injury via modulating macrophage polarization.
Oxid Med Cell Longev. 2021:66621562021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren HZ, Xia SZ, Qin XQ, Hu AY and Wang JL:
FOXO1 alleviates liver ischemia-reperfusion injury by regulating
the Th17/Treg ratio through the AKT/Stat3/FOXO1 pathway. J Clin
Transl Hepatol. 10:1138–1147. 2022.PubMed/NCBI
|
|
22
|
Wang C, Yang Z, Xu E, Shen X, Wang X, Li
Z, Yu H, Chen K, Hu Q, Xia X, et al: Apolipoprotein C-II induces
EMT to promote gastric cancer peritoneal metastasis via
PI3K/AKT/mTOR pathway. Clin Transl Med. 11:e5222021.PubMed/NCBI
|
|
23
|
Zhang L, Ren CF, Yang Z, Gong LB, Wang C,
Feng M and Guan WX: Forkhead Box S1 mediates epithelial-mesenchymal
transition through the Wnt/β-catenin signaling pathway to regulate
colorectal cancer progression. J Transl Med. 20:3272022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu X, Zhang P, Martin RC, Cui G, Wang G,
Tan Y, Cai L, Lv G and Li Y: Lack of fibroblast growth factor 21
accelerates metabolic liver injury characterized by
steatohepatities in mice. Am J Cancer Res. 6:1011–1125.
2016.PubMed/NCBI
|
|
25
|
Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS,
Hwang SG, An S, Yoon G, Gye MC, Yi JM, et al: Claudin-1 induces
epithelial-mesenchymal transition through activation of the
c-Abl-ERK signaling pathway in human liver cells. Oncogene.
32:4873–4882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen F, Gao Q, Wei A, Chen X, Shi Y, Wang
H and Cao W: Histone deacetylase 3 aberration inhibits Klotho
transcription and promotes renal fibrosis. Cell Death Differ.
28:1001–1012. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun W, Fu S, Wu S and Tu R: Growing
evidence of exosomal MicroRNA-related metastasis of hepatocellular
carcinoma. Biomed Res Int. 2020:45014542020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang W, Chen Z, Zhang W, Cheng Y, Zhang B,
Wu F, Wang Q, Wang S, Rong D, Reiter FP, et al: The mechanisms of
sorafenib resistance in hepatocellular carcinoma: Theoretical basis
and therapeutic aspects. Signal Transduct Target Ther. 5:872020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang
PY, Xiong YQ, Zhu XD, Xu HX, Kong LQ, Wu WZ, et al: Sorafenib
down-regulates expression of HTATIP2 to promote invasiveness and
metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Gastroenterology. 143:1641–1649.e5. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim E, Lisby A, Ma C, Lo N, Ehmer U, Hayer
KE, Furth EE and Viatour P: Promotion of growth factor signaling as
a critical function of β-catenin during HCC progression. Nat
Commun. 10:19092019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Valenta T, Hausmann G and Basler K: The
many faces and functions of β-catenin. EMBO J. 31:2714–2736. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Potthoff MJ: FGF21 and metabolic disease
in 2016: A new frontier in FGF21 biology. Nat Rev Endocrinol.
13:74–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lewis JE, Ebling FJP, Samms RJ and
Tsintzas K: Going back to the biology of FGF21: New insights.
Trends Endocrinol Metab. 30:491–504. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Geng L, Lam KSL and Xu A: The therapeutic
potential of FGF21 in metabolic diseases: From bench to clinic. Nat
Rev Endocrinol. 16:654–667. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu W, Li X and Luo Y: FGF21 in obesity and
cancer: New insights. Cancer Lett. 499:5–13. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang X, Yu C, Jin C, Yang C, Xie R, Cao
D, Wang F and McKeehan WL: Forced expression of hepatocyte-specific
fibroblast growth factor 21 delays initiation of chemically induced
hepatocarcinogenesis. Mol Carcinog. 45:934–942. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zheng Q, Martin RC, Shi X, Pandit H, Yu Y,
Liu X, Guo W, Tan M, Bai O, Meng X and Li Y: Lack of FGF21 promotes
NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling.
Theranostics. 10:9923–9936. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu ZY, Luo Y, Fang AP, Wusiman M, He TT,
Liu XZ, Yishake D, Chen S, Lu XT, Zhang YJ and Zhu HL: High serum
fibroblast growth factor 21 is associated with inferior
hepatocellular carcinoma survival: A prospective cohort study.
Liver Int. 42:663–673. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin YT and Wu KJ: Epigenetic regulation of
epithelial-mesenchymal transition: Focusing on hypoxia and TGF-β
signaling. J Biomed Sci. 27:392020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu Y, Zheng Y, Dai M, Wang X, Wu J, Yu B,
Zhang H, Cui Y, Kong W, Wu H and Yu X: G9a and histone deacetylases
are crucial for Snail2-mediated E-cadherin repression and
metastasis in hepatocellular carcinoma. Cancer Sci. 110:3442–3452.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song X, Wang J, Zheng T, Song R, Liang Y,
Bhatta N, Yin D, Pan S, Liu J, Jiang H and Liu L: LBH589 inhibits
proliferation and metastasis of hepatocellular carcinoma via
inhibition of gankyrin/STAT3/Akt pathway. Mol Cancer. 12:1142013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xiao Q, Liu H, Wang HS, Cao MT, Meng XJ,
Xiang YL, Zhang YQ, Shu F, Zhang QG, Shan H and Jiang GM: Histone
deacetylase inhibitors promote epithelial-mesenchymal transition in
hepatocellular carcinoma via AMPK-FOXO1-ULK1 signaling
axis-mediated autophagy. Theranostics. 10:10245–10261. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xu W, Liu H, Liu ZG, Wang HS, Zhang F,
Wang H, Zhang J, Chen JJ, Huang HJ, Tan Y, et al: Histone
deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation
and stabilization of Snail to promote metastasis of hepatoma cells.
Cancer Lett. 420:1–13. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ji H, Zhou Y, Zhuang X, Zhu Y, Wu Z, Lu Y,
Li S, Zeng Y, Lu QR, Huo Y, et al: HDAC3 deficiency promotes liver
cancer through a defect in H3K9ac/H3K9me3 transition. Cancer Res.
79:3676–3688. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cui G, Martin RC, Jin H, Liu X, Pandit H,
Zhao H, Cai L, Zhang P, Li W and Li Y: Up-regulation of FGF15/19
signaling promotes hepatocellular carcinoma in the background of
fatty liver. J Exp Clin Cancer Res. 37:1362018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim GY, Kwon JH, Cho JH, Zhang L,
Mansfield BC and Chou JY: Downregulation of pathways implicated in
liver inflammation and tumorigenesis of glycogen storage disease
type Ia mice receiving gene therapy. Hum Mol Genet. 26:1890–1899.
2017. View Article : Google Scholar : PubMed/NCBI
|
